Dr. Anthony A. Bavry, MD
Interventional Cardiology (Interventional Cardiology Physician)
- Medicare participating
At a glance
- Medical school
- University of Florida College of Medicine (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 677
Licensed in Texas since 2020, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: University of Florida College of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Interventional Cardiology Physician primary
TX license S5118 (first issued 2020; active) · FL license ME101504 · FL license ME 101504 -
Cardiovascular Disease Physician
FL license ME 101504
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
Medical groups
- University of Texas Southwestern Medical Center at Dallas (3,187 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 677
- Services billed
- 1,231
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 384 | 256 |
| Established patient office or other outpatient visit, 30-39 minutes | 117 | 102 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 95 | 93 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 68 | 65 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 66 | 44 |
| New patient office or other outpatient visit, 60-74 minutes | 51 | 51 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 41 | 41 |
| Established patient office or other outpatient visit, 40-54 minutes | 39 | 31 |
| New patient office or other outpatient visit, 45-59 minutes | 34 | 34 |
| Replacement of aortic valve through the skin and femoral artery | 31 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Amlodipine Besylate Other prescribers in Dallas, TX | 72 |
| Atorvastatin Calcium Other prescribers in Dallas, TX | 65 |
| Losartan Potassium Other prescribers in Dallas, TX | 64 |
| Eliquis (apixaban) Other prescribers in Dallas, TX | 41 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Dallas, TX | 41 |
| Metoprolol Succinate Other prescribers in Dallas, TX | 40 |
| Carvedilol Other prescribers in Dallas, TX | 38 |
| Furosemide Other prescribers in Dallas, TX | 35 |
| Rosuvastatin Calcium Other prescribers in Dallas, TX | 21 |
| Warfarin Sodium Other prescribers in Dallas, TX | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 25 payments worth $2,806 in total to this clinician.
| Edwards Lifesciences Corporation | $2,201 |
|---|---|
| W. L. Gore & Associates, Inc. | $172 |
| Abbott Laboratories | $155 |
| Medtronic, Inc. | $119 |
| Abiomed | $115 |
| Angiodynamics, Inc. | $43.64 |
| Food and Beverage | $1,868 |
|---|---|
| Travel and Lodging | $938 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Edwards Lifesciences Corporation Sep 23, 2025 | Travel and Lodging travel to Nashville, TN · in-kind | $459 |
| Edwards Lifesciences Corporation Nov 25, 2025 | Travel and Lodging travel to Nashville, TN · in-kind | $375 |
| Edwards Lifesciences Corporation Dec 8, 2025 | Travel and Lodging travel to Nashville, TN · in-kind | $98.99 |
| Edwards Lifesciences Corporation Sep 25, 2025 | Travel and Lodging travel to Nashville, TN · in-kind | $4.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $159,817 in research payments for these studies, mostly to the institutions running them.
- The PROGRESS Trial – Continued Access 2021-01-CAP
Edwards Lifesciences Corporation - NCT05932615--ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
Abbott Laboratories - The PROGRESS Trial 2021-01
Edwards Lifesciences Corporation - ALT-FLOW II 2022-06
Edwards Lifesciences Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.